Search Results - "Hendrick, Victoria M"

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 by Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Baniecki, MaryLynn, Hendrick, Victoria M, Damle, Bharat, Simón-Campos, Abraham, Pypstra, Rienk, Rusnak, James M

“…Nirmatrelvir is an M pro inhibitor active against SARS-CoV-2 and is given with ritonavir, a pharmacokinetic enhancer. In this double-blind, placebo-controlled…”
Get full text

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections by Chan, Phylinda L.S., McFadyen, Lynn, Quaye, Andrea, Leister‐Tebbe, Heidi, Hendrick, Victoria M., Hammond, Jennifer, Raber, Susan

“…A model‐informed drug development approach was used to select ceftaroline fosamil high‐dose regimens for pediatric patients with complicated skin and…”
Get full text

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 by Hammond, Jennifer, Fountaine, Robert J., Yunis, Carla, Fleishaker, Dona, Almas, Mary, Bao, Weihang, Wisemandle, Wayne, Baniecki, Mary Lynn, Hendrick, Victoria M., Kalfov, Veselin, Simón-Campos, J. Abraham, Pypstra, Rienk, Rusnak, James M.

“…In fully vaccinated patients with risk factors for severe disease and patients (vaccinated or unvaccinated) without such risk factors, nirmatrelvir–ritonavir…”
Get full text

Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19 by Hammond, Jennifer, Yunis, Carla, Fountaine, Robert J., Luscan, Gerald, Burr, Aimee M., Zhang, Wuyan, Wisemandle, Wayne, Soares, Holly, Baniecki, Mary Lynn, Hendrick, Victoria M., Kalfov, Veselin, Pypstra, Rienk, Rusnak, James M.

“…In this randomized trial, adults who had been exposed to a household contact with Covid-19 were given nirmatrelvir–ritonavir or placebo. Prophylaxis with…”
Get full text

Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis by Bradley, John S., Stone, Gregory G., Chan, Phylinda L. S., Raber, Susan R., Riccobene, Todd, Mas Casullo, Veronica, Yan, Jean Li, Hendrick, Victoria M., Hammond, Jennifer, Leister-Tebbe, Heidi K.

“…BACKGROUND:With increasing antimicrobial resistance, antibiotic treatment options for neonatal late-onset sepsis (LOS) are becoming limited. Primary objective…”
Get full text